title: Resveratrol Supplementation in Schizophrenia Patients: A Randomized Clinical Trial Evaluating Serum Glucose and Cardiovascular Risk Factors.
abstract: BACKGROUND
  Patients with schizophrenia (SZ) are generally overweight or obese and have several metabolic disorders. Additionally, such patients have a lower life expectancy and the main cause of their increased mortality is cardiovascular disease (CVD). The objective of this study was to determine the efficacy of resveratrol supplementation on serum glucose and CVD risk factors in individuals with SZ.
  
  
  RESULTS
  This is a four-week randomized, double-blind controlled trial (registration No.: NCT 02062190) in which 19 men with a diagnosis of SZ, aged 18 to 65, were assigned to either a resveratrol supplement group (200 mg/day) or a placebo group (200 mg/day). In short, we did not observe significant changes after resveratrol supplementation. In the placebo group, we found a significant increase in total cholesterol levels (p = 0.024) and in LDL-cholesterol (p = 0.002), as well as a decrease in body fat percentage (p = 0.038). The placebo group also showed an increase in triglycerides (9.19%) and a reduction in HDL-cholesterol (4.88%). In the resveratrol group, triglycerides decreased (7.64%).
  
  
  CONCLUSIONS
  In summary, oral resveratrol in reasonably low dosages (200 mg daily) brought no differences to body weight, waist circumference, glucose, and total cholesterol. It was possible to note that the lipid profile in the placebo group worsened and, although no significant differences were found, we can assume that resveratrol might prevent lipid profile damage and that the intervention affected the lipoprotein metabolism at various levels.
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. karine.personaldiet@gmail.com.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. karine.personaldiet@gmail.com.
authors: Karine
authors: K
authors: Zortea
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. vcarvalhofranco@gmail.com.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. vcarvalhofranco@gmail.com.
authors: Viviane C
authors: VC
authors: Franco
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. le.petter@ig.com.br.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. le.petter@ig.com.br.
authors: Lenise P
authors: LP
authors: Francesconi
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. keila.cereser@uol.com.br.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. keila.cereser@uol.com.br.
authors: Keila M M
authors: KM
authors: Cereser
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. mirlobato@gmail.com.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. mirlobato@gmail.com.
authors: Maria Inês R
authors: MI
authors: Lobato
authors: Schizophrenia Program, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, RS, Brazil. pbabreu@gmail.com.|Postgraduate Program in Medicine: Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre 90035-903, RS, Brazil. pbabreu@gmail.com.
authors: Paulo S
authors: PS
authors: Belmonte-de-Abreu
mesh_terms: D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D002784:Cholesterol / Q000097:blood; D019587:Dietary Supplements; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000494:pharmacology; D000077185:Resveratrol; D012307:Risk Factors; D012559:Schizophrenia / Q000097:blood*; D013267:Stilbenes / Q000494:pharmacology*; D014280:Triglycerides / Q000097:blood*; D055815:Young Adult
chemical_list: D000975:Antioxidants; D001786:Blood Glucose; D010936:Plant Extracts; D013267:Stilbenes; D014280:Triglycerides; D002784:Cholesterol; D000077185:Resveratrol
keywords: cardiovascular disease; cholesterol; resveratrol; schizophrenia